NASDAQ:BCDA

Biocardia Stock Insider Trading

etoro logo Buy BCDA
*Your capital is at risk
$0.87
-0.0256 (-2.84%)
At Close: Jun 03, 2026

BioCardia Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 5.34M and sold 0 BCDA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
100.00
Buy 5.34M shares
Sell 0 shares
100% Buy Activity
Moderate Negative Correlation
Buy Signal High Confidence
Feb 23, 2026

Analysis Breakdown:

  • Strongly supported by a very high Insider Power Score of 100.
  • Confidence increased due to high data reliability score of 100.
  • Supported by overwhelming buy-side pressure (100% buys).

Historical Insider Trades

Date Type Person Role Amount
May 20, 2026
Buy
Common Stock
P-Purchase
Altman Peter
President And CEO
CEO / President 1 500
Value: $1K
May 19, 2026
Buy
Common Stock
P-Purchase
Altman Peter
President And CEO
CEO / President 200
Value: $190
May 18, 2026
Buy
Common Stock
P-Purchase
Altman Peter
President And CEO
CEO / President 5 700
Value: $5K
May 15, 2026
Buy
Common Stock
P-Purchase
Altman Peter
President And CEO
CEO / President 5 100
Value: $5K
Apr 29, 2026
Buy
Common Stock
P-Purchase
Altman Peter
President And CEO
CEO / President 5 000
Value: $6K
Apr 21, 2026
Buy
Common Stock
P-Purchase
Altman Peter
President And CEO
CEO / President 400
Value: $492
Apr 20, 2026
Buy
Common Stock
P-Purchase
Altman Peter
President And CEO
CEO / President 600
Value: $738
Mar 25, 2026
Buy
Common Stock
P-Purchase
Altman Peter
President And CEO
CEO / President 300
Value: $366
Mar 24, 2026
Buy
Common Stock
P-Purchase
Altman Peter
President And CEO
CEO / President 600
Value: $744
Feb 04, 2026
Buy
Common Stock
P-Purchase
Altman Peter
President And CEO
CEO / President 5 000
Value: $6K
Jan 21, 2026
Buy
Common Stock
P-Purchase
Altman Peter
President And CEO
CEO / President 300
Value: $402
Jan 20, 2026
Buy
Common Stock
P-Purchase
Altman Peter
President And CEO
CEO / President 600
Value: $792
Dec 17, 2025
Buy
Common Stock
P-Purchase
Altman Peter
President And CEO
CEO / President 900
Value: $1K
Dec 16, 2025
Buy
Common Stock
P-Purchase
Altman Peter
President And CEO
CEO / President 200
Value: $274
Dec 08, 2025
Buy
Stock Option (right to buy)
A-Award
Blank Andrew Scott
Director
Director 12 000
Value: $16.4K
Dec 08, 2025
Buy
Stock Option (right to buy)
A-Award
Moyes Jay M
Director
Director 12 000
Value: $16.4K
Dec 08, 2025
Buy
Stock Option (right to buy)
A-Award
Allen Jim L.
Director
Director 12 000
Value: $16.4K
Dec 08, 2025
Buy
Common Stock
F-InKind
Gillis Edward M
Senior Vice President, Devices
CEO / President 15 172
Value: $20.8K
Dec 08, 2025
Buy
Stock Option (right to buy)
A-Award
Mcclung David
Chief Financial Officer
C-Suite Officer 27 000
Value: $37.0K
Dec 08, 2025
Buy
Stock Option (right to buy)
A-Award
Altman Peter
President And CEO
CEO / President 38 000
Value: $52.1K
Dec 08, 2025
Buy
Common Stock
F-InKind
Altman Peter
President And CEO
CEO / President 56 484
Value: $77.4K
Dec 08, 2025
Buy
Common Stock
A-Award
Altman Peter
President And CEO
CEO / President 106 588
Value: $146.0K
Dec 08, 2025
Buy
Common Stock
A-Award
Mcclung David
Chief Financial Officer
C-Suite Officer 58 276
Value: $79.8K
Dec 08, 2025
Buy
Common Stock
F-InKind
Mcclung David
Chief Financial Officer
C-Suite Officer 29 339
Value: $40.2K
Dec 08, 2025
Buy
Common Stock
A-Award
Gillis Edward M
Senior Vice President, Devices
CEO / President 38 078
Value: $52.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT BIOCARDIA, INC.
BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE